Startseite Adenosine deaminase, dipeptidyl peptidase-IV activities and lipid peroxidation are increased in the saliva of obese young adult
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Adenosine deaminase, dipeptidyl peptidase-IV activities and lipid peroxidation are increased in the saliva of obese young adult

  • Eduardo Ottobelli Chielle , Gabriela Bonfanti , Karine Santos De Bona , Rafael Noal Moresco und Maria Beatriz Moretto EMAIL logo
Veröffentlicht/Copyright: 20. Dezember 2014
Veröffentlichen auch Sie bei De Gruyter Brill
Manuskript einreichen Informationen für Autor*innen
Clinical Chemistry and Laboratory Medicine (CCLM)
Aus der Zeitschrift Clinical Chemistry and Laboratory Medicine (CCLM) Band 53 Heft 7

Abstract

Background: Obesity is the hallmark of the metabolic syndrome representing a major global health problem. It is considered a state of chronic inflammation with minimal exploration of salivary biomarkers. Thus, the intent of the present study was to assess the activities of salivary dipeptidyl peptidase IV (DPP-IV), adenosine deaminase (ADA) and lipid peroxidation in obese young and overweight young subjects.

Methods: ADA, DPP-IV activities and lipid peroxidation were investigated in saliva, as well as insulin, glucose, HbA1c, HOMA and anthropometric measurements in 149 young adults, including 54 with normal weight, 27 overweight and 68 obese subjects.

Results: Salivary ADA and DPP-IV activities as well as lipid peroxidation were higher in patients with obesity compared to the normal weight group. Correlations between ADA/DPP-IV activities, lipid peroxidation/ADA activity, ADA activity/hip circumference and BMI/weight were observed.

Conclusions: Our results indicate that the increase in the salivary ADA and DPP-IV activities as well as in the lipid peroxidation could be related of the regulation to various aspects of adipose tissue function and inflammatory obesity. It is suggested that these salivary biomarkers may be used as biochemical test in clinical abnormalities present in obesity, in the absence of oral inflammatory diseases.

Keywords: adenosine deaminase; dipeptidyl peptidase-IV; lipid peroxidation; obesity; saliva
Corresponding author: Maria Beatriz Moretto, Postgraduate Program in Pharmaceutical Sciences, Department of Clinical and Toxicology Analysis, Center of Healthy Sciences, Federal University of Santa Maria (UFSM), 97105-900 Santa Maria, RS, Brazil, Fax: +55 3220 8018, E-mail:

Acknowledgments

The authors wish to thank the Federal University of Santa Maria (UFSM), and University of West of Santa Catarina (UNOESC), SC, Brazil, for support in this study. Also, we thank all the volunteers who participated in this study.

Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Financial support: The work had the financial support of the Brazilian National Research Council (CNPq), Universal no 477029/2011-6.

Employment or leadership: None declared.

Honorarium: None declared.

Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

1. Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014;384:766–81.10.1016/S0140-6736(14)60460-8Suche in Google Scholar

2. Esser N, Legrand-Poels S, Piette J, Scheen AJ, Paquot N. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract 2014;105:141–50.10.1016/j.diabres.2014.04.006Suche in Google Scholar

3. Ghigliotti G, Barisione C, Garibaldi S, Fabbi P, Brunelli C, Spallarossa P, et al. Adipose tissue immune response: novel triggers and consequences for chronic inflammatory conditions. Inflammation 2014;37:1337–53.10.1007/s10753-014-9914-1Suche in Google Scholar

4. Karalis KP, Giannogonas P, Kodela E, Koutmani Y, Zoumakis M, Teli T. Mechanisms of obesity and related pathology: linking immune responses to metabolic stress. FEBS J 2009;276: 5747–54.10.1111/j.1742-4658.2009.07304.xSuche in Google Scholar

5. Kuno M, Seki N, Tsujimoto S, Nakanishi I, Kinoshita T, Nakamura K, et al. Anti-inflammatory activity of non-nucleoside adenosine deaminase inhibitor FR234938. Eur J Pharmacol 2006;534:241–9.10.1016/j.ejphar.2006.01.042Suche in Google Scholar

6. Haskó G, Cronstein BN. Adenosine: an endogenous regulator of innate immunity. Trends Immunol 2004;25:33–9.10.1016/j.it.2003.11.003Suche in Google Scholar

7. Khemka VK, Bagchi D, Ghosh A, Sen O, Bir A, Chakrabarti S, et al. Raised serum adenosine deaminase level in nonobese type 2 diabetes mellitus. Sci World J 2013;2013:404320.10.1155/2013/404320Suche in Google Scholar

8. Yazbeck R, Howarth GS, Abbott CA. Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease? Trends Pharmacol Sci 2009;30:600–7.10.1016/j.tips.2009.08.003Suche in Google Scholar

9. Deacon CF, Carr RD, Holst JJ. DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes. Front Biosci 2008;13:1780–94.10.2741/2799Suche in Google Scholar

10. Mentlein R. Dipeptidyl-peptidase IV (CD26) – role in the inactivation of regulatory peptides. Regul Pept 1999;85: 9–24.10.1016/S0167-0115(99)00089-0Suche in Google Scholar

11. Matteucci E, Giampietro O. Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the enzyme. Curr Med Chem Rev 2009;16:2943–51.10.2174/092986709788803114Suche in Google Scholar PubMed

12. Kobayashi S, Ohnuma K, Uchiyama M, Iino K, Iwata S, Dang NH, et al. Association of CD26 with CD45RA outside lipid rafts attenuates cord blood T-cell activation. Blood 2004;103:1002–10.10.1182/blood-2003-08-2691Suche in Google Scholar PubMed

13. De Bona KS, Bonfanti G, Cargnelutti LO, Bitencourt PE, da Silva PS, Ceolin R, et al. Lymphocytic enzymes and lipid peroxidation in patients with metabolic syndrome. Clin Biochem 2012;45:1081–5.10.1016/j.clinbiochem.2012.06.010Suche in Google Scholar PubMed

14. Bellé LP, Bitencourt PE, De Bona KS, Moresco RN, Moretto MB. Association between HbA1c and dipeptidyl peptidase IV activity in type 2 diabetes mellitus [Letter to the Editor]. Clin Chim Acta 2012;413:1020–1.10.1016/j.cca.2012.02.021Suche in Google Scholar PubMed

15. Al-Rawi NH. Oxidative stress, antioxidant status and lipid profile in the saliva of type 2 diabetics. Diab Vasc Dis Res 2011;8:22–8.10.1177/1479164110390243Suche in Google Scholar PubMed

16. Sorrentino SA, Besler C, Rohrer L, Meyer M, Heinrich K, Bahlmann FH, et al. Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation 2010;121:110–22.10.1161/CIRCULATIONAHA.108.836346Suche in Google Scholar PubMed

17. De Almeida PD, Grégio AM, Machado MA, De Lima AA, Azevedo LR. Saliva composition and functions: a comprehensive review. J Contemp Dent Pract 2008;9:72–80.10.5005/jcdp-9-3-72Suche in Google Scholar

18. Malamud D, Rodriguez-Chavez IR. Saliva as a diagnostic fluid. Dent Clin North Am 2011;55:159–78.10.1016/j.cden.2010.08.004Suche in Google Scholar PubMed PubMed Central

19. Takagi K, Ishikura Y, Hiramatsu M, Nakamura K, Degawa M. Development of a saliva collection device for use in the field. Clin Chim Acta 2013;425:181–5.10.1016/j.cca.2013.08.008Suche in Google Scholar PubMed

20. De Bona KS, Bonfanti G, Bitencourt PE, Cargnelutti LO, da Silva PS, De Lucca L, et al. Butyrylcholinesterase and γ-glutamyltransferase activities and oxidative stress markers are altered in metabolic syndrome, but are not affected by body mass index. Inflammation 2013;36:1539–47.10.1007/s10753-013-9697-9Suche in Google Scholar PubMed

21. Weiner JS, Lourie JA. Practical human biology. London: Academic Press, 1981.Suche in Google Scholar

22. James PT, Leach R, Kalamara E, Shayeghi M. The worldwide obesity epidemic. Obes Res 2001;12:S228–33.10.1038/oby.2001.123Suche in Google Scholar

23. Gallagher D, Heymsfield SB, Heo M, Jebb SA, Murgatroyd PR, Sakamoto Y. Healthy percentage body fat ranges: an approach for developing guidelines based on body mass index. Am J Clin Nutr 2000;12:694–701.10.1093/ajcn/72.3.694Suche in Google Scholar

24. Ashwell M, Hsieh SD. Six reasons why the waist-to-height ratio is a rapid and effective global indicator for health risks of obesity and how its use could simplify the international public health message on obesity. Int J Food Sci Nutr 2005;12:303–7.10.1080/09637480500195066Suche in Google Scholar

25. Sereg, M, Judit T, Attila P, Ibolya V, Péter I, Nikolette S, et al. Diagnostic performance of salivary cortisol and serum osteocalcin measurements in patients with overt and subclinical LCushing’s syndrome. Steroids 2011;76:38–42.10.1016/j.steroids.2010.08.007Suche in Google Scholar

26. Nagatsu T, Hino M, Fuyamada H, Hayakawa T, Sakakibara S. New chromogenic substrates for Xprolyl dipeptidyl-aminopeptidase. Anal Biochem 1976;74:466–76.10.1016/0003-2697(76)90227-XSuche in Google Scholar

27. Lapenna GD, Ciofani SD, Pierdomenico MA, Giamberardino MA, Cuccurullo F. Reaction conditions affecting the relationship between thiobarbituric acid reactivity and lipid peroxides in human plasma. Free Radic Biol Med 2001;31:331–5.10.1016/S0891-5849(01)00584-6Suche in Google Scholar

28. Vroegrijk IO, van Klinken JB, van Diepen JA, van den Berg SA, Febbraio M, Steinbusch LK, et al. CD36 is important for adipocyte recruitment and affects lipolysis. Obesity (Silver Spring) 2013;21:2037–45.10.1002/oby.20354Suche in Google Scholar PubMed

29. Johansson SM, Lindgren E, Yang JN, Herling AW, Fredholm BB. Adenosine A1 receptors regulate lipolysis and lipogenesis in mouse adipose tissue-interactions with insulin. Eur J Pharmacol 2008;597:92–101.10.1016/j.ejphar.2008.08.022Suche in Google Scholar PubMed

30. Frühbeck G, Gómez-Ambrosi J, Salvador J. Leptin induced lipolysis opposes the tonic inhibition of endogenous adenosine in white adipocytes. FASEB J 2001;15:333–40.10.1096/fj.00-0249comSuche in Google Scholar PubMed

31. Kurtul N, Pence S, Akarsu E, Kocoglu H, Aksoy Y, Aksoy H. Adenosine deaminase activity in the serum of type 2 diabetic patients. Acta Med (Hradec Kralove) 2004;47:33–5.10.14712/18059694.2018.63Suche in Google Scholar

32. Katagiri D, Hamasaki Y, Doi K, Okamoto K, Negishi K, Nangaku M, et al. Protection of glucagon-like peptide-1 in cisplatin-induced renal injury elucidates gut-kidney connection. J Am Soc Nephrol 2013;24:2034–43.10.1681/ASN.2013020134Suche in Google Scholar PubMed PubMed Central

33. Kos K, Baker AR, Jernas M, Harte AL, Clapham JC, O’Hare JP, et al. DPP-IV inhibition enhances the antilipolytic action of NPY in human adipose tissue. Diabetes Obes Metab 2009;11:285–92.10.1111/j.1463-1326.2008.00909.xSuche in Google Scholar PubMed

34. Yu DM, Slaitini L, Gysbers V, Riekhoff AG, Kähne T, Knott HM, et al. Soluble CD26/dipeptidyl peptidase IV enhances human lymphocyte proliferation in vitro independent of dipeptidyl peptidase enzyme activity and adenosine deaminase binding. Scand J Immunol 2011;73:102–11.10.1111/j.1365-3083.2010.02488.xSuche in Google Scholar PubMed

35. Lamers D, Famulla S, Wronkowitz N, Hartwig S, Lehr S, Ouwens M, et al. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes 2011;60:1917–25.10.2337/db10-1707Suche in Google Scholar PubMed PubMed Central

36. Mannucci E, Pala L, Ciani S, Bardini G, Pezzatini A, Sposato I, et al. Hyperglycaemia increases dipeptidy peptidase IV activity in diabetes mellitus. Diabetologia 2005;48:1168–72.10.1007/s00125-005-1749-8Suche in Google Scholar PubMed

37. Kirino Y, Sato Y, Kamimoto T, Kawazoe K, Minakuchi K. Altered dipeptidyl peptidase-4 activity during the progression of hyperinsulinemic obesity and islet atrophy in spontaneously late-stage type 2 diabetic rats. Am J Physiol Endocrinol Metab 2011;300:372–9.10.1152/ajpendo.00319.2010Suche in Google Scholar PubMed

Received: 2014-11-5
Accepted: 2014-11-20
Published Online: 2014-12-20
Published in Print: 2015-6-1

©2015 by De Gruyter

Artikel in diesem Heft

  1. Frontmatter
  2. Editorial
  3. Personalized medicine: moving from simple theory to daily practice
  4. Evaluating and using innovative technologies: a lesson from Theranos?
  5. Review
  6. Emerging biomarkers in the detection and prognosis of prostate cancer
  7. Mini Review
  8. Could molecular assessment of calcium metabolism be a useful tool to early screen patients at risk for pre-eclampsia complicated pregnancy? Proposal and rationale
  9. Opinion Papers
  10. Is laboratory medicine ready for the era of personalized medicine? A survey addressed to laboratory directors of hospitals/academic schools of medicine in Europe
  11. Theranos phenomenon: promises and fallacies
  12. Clinical laboratories: production industry or medical services?
  13. Genetics and Molecular Diagnostics
  14. Role of JAK2 V617F mutation and aberrant expression of microRNA-143 in myeloproliferative neoplasms
  15. Direct identification of Gram-positive bacteria and resistance determinants from blood cultures using a microarray-based nucleic acid assay: in-depth analysis of microarray data for undetermined results
  16. General Clinical Chemistry and Laboratory Medicine
  17. Comparison between bottom-up and top-down approaches in the estimation of measurement uncertainty
  18. Role of vitamin D and sFlt-1/PlGF ratio in the development of early- and late-onset preeclampsia
  19. Adenosine deaminase, dipeptidyl peptidase-IV activities and lipid peroxidation are increased in the saliva of obese young adult
  20. PON-1 and ferroxidase activities in older patients with mild cognitive impairment, late onset Alzheimer’s disease or vascular dementia
  21. Comparison of five automated hematology analyzers in a university hospital setting: Abbott Cell-Dyn Sapphire, Beckman Coulter DxH 800, Siemens Advia 2120i, Sysmex XE-5000, and Sysmex XN-2000
  22. Dacryocytes are a common morphologic feature of autoimmune and microangiopathic haemolytic anaemia
  23. Performance characteristics of a new automated method for measurement of anti-cyclic citrullinated peptide
  24. The clinical performance of a chemiluminescent immunoassay in detecting anti-cardiolipin and anti-β2 glycoprotein I antibodies. A comparison with a homemade ELISA method
  25. Reference Values and Biological Variations
  26. Reference interval for immature platelet fraction on Sysmex XN hematology analyzer: a comparison study with Sysmex XE-2100
  27. Development of the first urinary reproductive hormone ranges referenced to independently determined ovulation day
  28. Cancer Diagnostics
  29. Urinary miR-183 and miR-205 do not surpass PCA3 in urine as predictive markers for prostate biopsy outcome despite their highly dysregulated expression in prostate cancer tissue
  30. Cardiovascular Diseases
  31. Elevated circulating levels of lipoprotein-associated phospholipase A2 in obese children
  32. Letters to the Editors
  33. Reporting of hemolysis index (HI) with laboratory results should be obligatory in newborns and infants
  34. Unmeasurably high chloride: a surrogate marker of thiocyanate poisoning identification
  35. Association between red cell distribution width and myocardial infarction in rheumatoid arthritis
  36. Plasmatic and urinary glycosaminoglycan profile in a patient affected by multiple sulfatase deficiency
  37. Rapid diagnosis of cryptococcal meningitis by Türk staining
  38. A high selectivity and sensitivity analytical method for the analysis of 8-hydroxy-2′-deoxyguanosine in the urine of Alzheimer’s disease patients
  39. S100B protein concentration measurement according to two different immunoassays
https://doi.org/10.1515/cclm-2014-1086
Schlagwörter für diesen Artikel
adenosine deaminase; dipeptidyl peptidase-IV; lipid peroxidation; obesity; saliva

Artikel in diesem Heft

  1. Frontmatter
  2. Editorial
  3. Personalized medicine: moving from simple theory to daily practice
  4. Evaluating and using innovative technologies: a lesson from Theranos?
  5. Review
  6. Emerging biomarkers in the detection and prognosis of prostate cancer
  7. Mini Review
  8. Could molecular assessment of calcium metabolism be a useful tool to early screen patients at risk for pre-eclampsia complicated pregnancy? Proposal and rationale
  9. Opinion Papers
  10. Is laboratory medicine ready for the era of personalized medicine? A survey addressed to laboratory directors of hospitals/academic schools of medicine in Europe
  11. Theranos phenomenon: promises and fallacies
  12. Clinical laboratories: production industry or medical services?
  13. Genetics and Molecular Diagnostics
  14. Role of JAK2 V617F mutation and aberrant expression of microRNA-143 in myeloproliferative neoplasms
  15. Direct identification of Gram-positive bacteria and resistance determinants from blood cultures using a microarray-based nucleic acid assay: in-depth analysis of microarray data for undetermined results
  16. General Clinical Chemistry and Laboratory Medicine
  17. Comparison between bottom-up and top-down approaches in the estimation of measurement uncertainty
  18. Role of vitamin D and sFlt-1/PlGF ratio in the development of early- and late-onset preeclampsia
  19. Adenosine deaminase, dipeptidyl peptidase-IV activities and lipid peroxidation are increased in the saliva of obese young adult
  20. PON-1 and ferroxidase activities in older patients with mild cognitive impairment, late onset Alzheimer’s disease or vascular dementia
  21. Comparison of five automated hematology analyzers in a university hospital setting: Abbott Cell-Dyn Sapphire, Beckman Coulter DxH 800, Siemens Advia 2120i, Sysmex XE-5000, and Sysmex XN-2000
  22. Dacryocytes are a common morphologic feature of autoimmune and microangiopathic haemolytic anaemia
  23. Performance characteristics of a new automated method for measurement of anti-cyclic citrullinated peptide
  24. The clinical performance of a chemiluminescent immunoassay in detecting anti-cardiolipin and anti-β2 glycoprotein I antibodies. A comparison with a homemade ELISA method
  25. Reference Values and Biological Variations
  26. Reference interval for immature platelet fraction on Sysmex XN hematology analyzer: a comparison study with Sysmex XE-2100
  27. Development of the first urinary reproductive hormone ranges referenced to independently determined ovulation day
  28. Cancer Diagnostics
  29. Urinary miR-183 and miR-205 do not surpass PCA3 in urine as predictive markers for prostate biopsy outcome despite their highly dysregulated expression in prostate cancer tissue
  30. Cardiovascular Diseases
  31. Elevated circulating levels of lipoprotein-associated phospholipase A2 in obese children
  32. Letters to the Editors
  33. Reporting of hemolysis index (HI) with laboratory results should be obligatory in newborns and infants
  34. Unmeasurably high chloride: a surrogate marker of thiocyanate poisoning identification
  35. Association between red cell distribution width and myocardial infarction in rheumatoid arthritis
  36. Plasmatic and urinary glycosaminoglycan profile in a patient affected by multiple sulfatase deficiency
  37. Rapid diagnosis of cryptococcal meningitis by Türk staining
  38. A high selectivity and sensitivity analytical method for the analysis of 8-hydroxy-2′-deoxyguanosine in the urine of Alzheimer’s disease patients
  39. S100B protein concentration measurement according to two different immunoassays
Jetzt anmelden und 20% sparen
Institutioneller Zugang
Wie funktioniert Authentifizierung?
Haben Sie eine Idee, wie wir unsere Website verbessern können?
Bitte schreiben Sie uns.
© 2025 De Gruyter Brill
Heruntergeladen am 17.9.2025 von https://www.degruyterbrill.com/document/doi/10.1515/cclm-2014-1086/html
Button zum nach oben scrollen